AU Patent

AU2009220942B2 — Methods of treatment employing prolonged continuous infusion of Belinostat

Assigned to Onxeo DK · Expires 2015-05-28 · 11y expired

What this patent protects

The present invention relates generally to the treatment of diseases and disorders that are mediated by histone deacetylase (HDAC), for example, cancer, with Belinostat

USPTO Abstract

The present invention relates generally to the treatment of diseases and disorders that are mediated by histone deacetylase (HDAC), for example, cancer, with Belinostat

Drugs covered by this patent

Patent Metadata

Patent number
AU2009220942B2
Jurisdiction
AU
Classification
—
Expires
2015-05-28
Drug substance claim
No
Drug product claim
No
Assignee
Onxeo DK
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.